importance of monitoring and early switch to second generation tyrosine kinase inhibitors for the prognosis of patients with chronic myeloid leukemia with imatinib resistance or intolerance
Clicks: 279
ID: 178388
2011
Imatinib mesylate was the first BCR-ABL-target agent approved for the treatment of chronic myeloid leukemia. Although most patients respond well to imatinib therapy, the literature shows that one third develops resistance or intolerance. The timing of second-line treatment after failure of initial treatment may have a significant impact on long-term outcome. Thus, appropriate monitoring to identify resistance and/or intolerance is crucial to early intervention with second generation tyrosine kinase inhibitors and attainment of better results
| Reference Key |
simes2011revistaimportance
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Belinda Pinto Simões;José Wilson Ramos Braga Junior;Maria Aparecida do Carmo Rego;Cármino Antônio de Souza |
| Journal | journal of computational and graphical statistics : a joint publication of american statistical association, institute of mathematical statistics, interface foundation of north america |
| Year | 2011 |
| DOI | 10.5581/1516-8484.20110017 |
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.